Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting
Farhat Butt,Helen Devonport
DOI: https://doi.org/10.2147/OPTH.S393662
2023-02-17
Clinical Ophthalmology
Abstract:Farhat Butt, Helen Devonport Opthalmology Department, Bradford Royal Infirmary, Duckworth Lane, BD9 6RJ, UK Correspondence: Farhat Butt, Bradford Royal Infirmary, Duckworth Lane, BD9 6RJ, UK, Tel +44 7834 922022, Fax +44 1274 364786, Email Purpose: The present study aimed to assess the efficacy and safety associated to the treatment of patients with non-infectious posterior uveitis with intravitreal dexamethasone (DEX) implants in a real-world clinical setting. Patients and Methods: This is a retrospective, single center analysis of the data from 29 patients with non-infectious posterior uveitis in whom 38 eyes were treated with dexamethasone intravitreal implants in routine clinical practice between January 2012 and October 2017. The parameters of visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) were recorded 6 weeks after the first implant was administered, in accordance with the clinical guidelines for the use of these implants, and after a 6-month follow-up period. In addition, the formation of cataracts was evaluated at 12 months. Results: Treatment with the DEX implant caused a significant improvement in the VA from baseline at 6 weeks in eyes treated with 2– 6 implants and for eyes without cataracts. A significant decrease in CRT was observed relative to the baseline at 6 weeks for eyes treated with 1 and 2– 6 implants, which was maintained at 6 months for those eyes treated with 2– 6 implants. This significant improvement in CRT at 6 weeks and 6 months was evident in eyes with and without cataracts. During the study period, the IOP was found to increase significantly from baseline at 6 weeks in some eyes but this was managed topically, and no surgical intervention was necessary. Conclusion: Intravitreal DEX implants represent an effective and safe therapy for the treatment of non-infectious uveitis in routine clinical practice, producing favorable visual and anatomical outcomes after the administration of just 2– 6 DEX implants. Keywords: visual acuity, intraocular pressure, central retinal thickness, cataracts, retrospective analysis Patients with non-infectious posterior uveitis may benefit from treatment with intravitreal dexamethasone (DEX) implants, although their efficacy and safety must first be demonstrated in a real-world clinical setting. As such, we assessed the efficacy of this therapy in a 6-month period after administering the first implant to 38 eyes of 29 patients with non-infectious posterior uveitis treated at our hospital between January 2012 and October 2017. We assessed efficacy through the improvement in visual acuity (VA) and central retinal thickness (CRT), as well as recording any common adverse events associated with the treatment, such as increased intraocular pressure (IOP) or cataract development in the 12 months after the first treatment. In eyes that received 2–6 DEX implants, VA improved significantly after 6 weeks and the CRT decreased (reflecting less inflammation of the retina), effects that persisted for 6 months in these eyes. Only a mild increase in IOP could be detected, which did not require surgery to be adequately managed, and cataract induction was not exacerbated by the DEX implants. Thus, intravitreal DEX implants are an effective and safe treatment for non-infectious posterior uveitis in routine clinical practice, producing favorable visual and anatomical outcomes after administering just 1–6 DEX implants. Uveitis refers to a group of infectious and non-infectious intraocular inflammatory diseases that lead to irreversible blindness in approximately 35% of patients, and that account for up to 15% of blindness in the developed world. 1,2 Unlike other ocular diseases, uveitis may occur at any age, although it most commonly affects adults of working-age, 1,3 with the ensuing social and economic impact. 4–6 The estimated average annual incidence of uveitis is 50.45 per 100,000, 1,7,8 with a geographic variation in prevalence from 9 to 730 cases per 100,000 individuals. 9 The main causes of the visual loss associated with uveitis are cystoid macular edema (CME), 3,4,10 which can provoke structural changes in the retina and cataracts, and complications associated with increased intraocular pressure (IOP). The majority of uveitis cases (67–90%) are non-infectious, 7,11–13 making this the third-leading cause of preventable blindness worldwide. 14 Uveitis is classified into anterior, intermediate and posterior according to the part of the uvea that is affected. 1 Posterior uveitis affects the choroid at the back of the eye, although it can also affect the retina and optic nerve, accounting for 15–22% of all uveitis cases 15 and representing the -Abstract Truncated-